A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants

NCT07608705 | Not Yet Recruiting Phase 1

• 1 other identifier: HRS-1301-105
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.

Conditions

Hyperlipidemias

Outcome Measures

Primary Outcomes (6)

• Maximum observed plasma concentration (Cmax)

  Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets.

  Up to 15 days.

• Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC 0-last)

  Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets.

  Up to 15 days.

• Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)

  Plasma pharmacokinetics (PK) parameters of Midazolam when administered alone and in combination with HRS-1301 tablets.

  Up to 15 days.

• Maximum observed plasma concentration (Cmax)

  Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets.

  Up to 18 days.

• Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUC0-last)

  Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets.

  Up to 18 days.

• Area under the plasma concentration-time curve from time 0 to infinity (AUC 0-inf)

  Plasma pharmacokinetics (PK) parameters of Atorvastatin when administered alone and in combination with HRS-1301 tablets.

  Up to 18 days.

Secondary Outcomes (15)

• Time to reach maximum observed concentration (Tmax)

  Up to 15 days.

• Terminal elimination half-life (t1/2)

  Up to 15 days.

• Apparent clearance (CL/F)

  Up to 15 days.

• Apparent volume of distribution (Vz/F)

  Up to 15 days.

• Maximum observed plasma concentration (Cmax)

  Up to 15 days.

Study Arms (1)

HRS-1301 and Midazolam or Atorvastatin Group

EXPERIMENTAL

HRS-1301 tablets and Midazolam oral solution or Atorvastatin Calcium tablets, specified dose on specified days.

Drug: HRS-1301 Tablets; Drug: Atorvastatin Calcium Tablets; Drug: Midazolam oral solution

Interventions

HRS-1301 Tablets DRUG

HRS-1301 tablets.

HRS-1301 and Midazolam or Atorvastatin Group

Atorvastatin Calcium Tablets DRUG

Atorvastatin Calcium tablets.

HRS-1301 and Midazolam or Atorvastatin Group

Midazolam oral solution DRUG

Midazolam oral solution.

HRS-1301 and Midazolam or Atorvastatin Group

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Subjects must be aged ≥ 18 years and ≤ 55 years on the day of signing the informed consent form (ICF);
• At screening, body mass index (BMI) must be ≥ 19.0 kg/m² and \< 28 kg/m², with body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females;
• Physical examination, vital signs, electrocardiogram (ECG), posteroanterior and lateral chest X-ray/CT, abdominal ultrasound, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and thyroid function) were normal or abnormal but of no clinical significance;
• Female participants must not be pregnant or lactating and must have negative pregnancy test results prior to investigational drug administration; participants must have had no unprotected sexual intercourse within two weeks prior to screening; female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with the contraception requirements for the duration specified in the protocol and have no plans to donate sperm or eggs;
• Subjects who understand the study procedures and methods, voluntarily agree to participate in this trial, and provide written informed consent (ICF).

You may not qualify if:

• Subjects with previous medical history or current diagnosis of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, infectious, immunological, malignant neoplastic, neurological, or psychiatric/metabolic disorders/dysfunctions, or any other disease;
• Subjects who have gastrointestinal, hepatic, renal, or other known diseases that may affect drug absorption, distribution, metabolism, or excretion, or that may reduce compliance;
• Subjects who have experienced severe trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial period;
• Subjects with a history of specific allergies, or with an allergic constitution, or with known hypersensitivity to any component of the investigational drug;
• Subjects who have used any medication within 2 weeks prior to screening, or who are still within 5 half-lives of any medication at the time of screening;
• Subjects who have participated in any other clinical trial of a drug or medical device within 3 months prior to screening, or who are still within 5 half-lives of a prior investigational drug at the time of screening;
• Subjects who have donated blood ≥ 200 mL or experienced significant blood loss (≥ 400 mL) within 4 weeks prior to screening, or who have received a blood transfusion within 8 weeks prior to screening;
• Subjects who have received a live (attenuated) vaccine within 4 weeks prior to screening or plan to receive such a vaccine during the trial period.

Sponsors & Collaborators

• Shandong Suncadia Medicine Co., Ltd.: lead

Study Sites (1)

Qilu Hospital of Shandong University

Jinan, Shandong, 250012, China

Location

MeSH Terms

Conditions

Hyperlipidemias

Interventions

Atorvastatin; Midazolam

Condition Hierarchy (Ancestors)

Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

Pyrroles; Azoles; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heptanoic Acids; Fatty Acids; Lipids; Benzodiazepines; Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Central Study Contacts

Ying Wang

CONTACT

+86-0518-82342973; ying.wang.yw30@hengrui.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: An open-label, single-arm, fixed-sequence, pharmacokinetics, safety and tolerability study.

Study Record Dates

• First Submitted: May 20, 2026
• First Posted: May 27, 2026
• Study Start: June 1, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: May 27, 2026

Record last verified: 2026-05

Locations

CN (1)